ATE296316T1 - Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung - Google Patents

Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung

Info

Publication number
ATE296316T1
ATE296316T1 AT00920645T AT00920645T ATE296316T1 AT E296316 T1 ATE296316 T1 AT E296316T1 AT 00920645 T AT00920645 T AT 00920645T AT 00920645 T AT00920645 T AT 00920645T AT E296316 T1 ATE296316 T1 AT E296316T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
production
directed against
antibodies directed
against human
Prior art date
Application number
AT00920645T
Other languages
English (en)
Inventor
Johannes Gerdes
Thomas Scholzen
Elmar Endl
Claudia Wohlenberg
Bettina Baron-Luhr
Margrit Hahn
Patricia Prilla
Johanna Szuwinski
Rolf Knippers
Original Assignee
Dakocytomation Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dakocytomation Denmark As filed Critical Dakocytomation Denmark As
Application granted granted Critical
Publication of ATE296316T1 publication Critical patent/ATE296316T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00920645T 1999-04-01 2000-03-31 Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung ATE296316T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19915057A DE19915057A1 (de) 1999-04-01 1999-04-01 Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
PCT/EP2000/002910 WO2000059943A2 (en) 1999-04-01 2000-03-31 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE

Publications (1)

Publication Number Publication Date
ATE296316T1 true ATE296316T1 (de) 2005-06-15

Family

ID=7903372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920645T ATE296316T1 (de) 1999-04-01 2000-03-31 Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung

Country Status (9)

Country Link
US (2) US6777194B1 (de)
EP (1) EP1165615B1 (de)
JP (1) JP4980516B2 (de)
AT (1) ATE296316T1 (de)
AU (1) AU4114800A (de)
DE (2) DE19915057A1 (de)
DK (1) DK1165615T3 (de)
ES (1) ES2239594T3 (de)
WO (1) WO2000059943A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143849A2 (en) 2007-05-14 2008-11-27 Historx, Inc. Compartment segregation by pixel characterization using image data clustering
ES2599902T3 (es) 2007-06-15 2017-02-06 Novartis Ag Sistema y método de microscopio para obtener datos de muestra normalizados
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
US7978258B2 (en) * 2007-08-31 2011-07-12 Historx, Inc. Automatic exposure time selection for imaging tissue
GB0720113D0 (en) 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
US9240043B2 (en) 2008-09-16 2016-01-19 Novartis Ag Reproducible quantification of biomarker expression
WO2016198833A2 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (de) 1985-11-01 1993-09-29 Xoma Corporation Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
AU9138891A (en) 1990-12-14 1992-07-08 Steven J. Mondre Nicotine-containing dental floss
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5876438A (en) * 1993-08-02 1999-03-02 Houston Biotechnology Incorporated Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6156500A (en) * 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US6303323B1 (en) 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies

Also Published As

Publication number Publication date
DE60020353T2 (de) 2006-01-26
JP2002541157A (ja) 2002-12-03
WO2000059943A2 (en) 2000-10-12
WO2000059943A3 (en) 2001-03-22
ES2239594T3 (es) 2005-10-01
EP1165615A2 (de) 2002-01-02
JP4980516B2 (ja) 2012-07-18
AU4114800A (en) 2000-10-23
DK1165615T3 (da) 2005-08-15
DE60020353D1 (de) 2005-06-30
EP1165615B1 (de) 2005-05-25
US6777194B1 (en) 2004-08-17
US20040146513A1 (en) 2004-07-29
DE19915057A1 (de) 2000-10-19

Similar Documents

Publication Publication Date Title
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
TW200500377A (en) Method of humanizing immune system molecules
DE69229275D1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
DE60333228D1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
EA200200503A1 (ru) Способ лечения ревматоидного артрита
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
DK0552296T3 (da) Monoklonale antistoffer fra mus
WO2004094473A3 (en) Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
ATE151078T1 (de) Verfahren und zwischenprodukte synthetischer antikörperderivate
EE200500012A (et) Peptiid-pähine passiivne immunoteraapia ateroskleroosi raviks
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
WO2004030607A3 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE335504T1 (de) Humanisierte antikörper zur erkennung von verotoxin ii sowie zellinie zur herstellung derselben
DE69937057D1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
MX2023013248A (es) Anticuerpos anti-tmprss6 y sus usos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties